Middle East war disrupts pharma air routes and raises risk of cancer drug shortages in Gulf

Elles De Yeager Avatar
3–4 minutes

War in the Middle East is disrupting the flow of critical medicines into the Gulf, forcing drugmakers to reroute temperature-sensitive shipments and raising the risk of shortages of cancer drugs and other treatments if the conflict continues. According to a report by Reuters, the shutdown and repeated disruption of key air hubs including Dubai, Abu Dhabi and Doha have broken established pharmaceutical logistics chains into the region.

Reuters reported that major shortages have not yet materialized, but industry executives warned that the risk is rising for medicines with short shelf lives and strict cold-chain requirements, including monoclonal antibodies used in cancer treatment. The report said companies are now rerouting cargo through airports in Saudi Arabia, Oman, Turkey, China and Singapore while trying to preserve temperature control and delivery times.

Drugmakers reroute cargo as Gulf air hubs face repeated disruption

Reuters reported that pharmaceutical companies normally rely on major Gulf hubs to move medicines quickly across the Middle East, Africa and parts of South Asia. With those routes repeatedly disrupted by the war, companies have shifted shipments through Saudi Arabia and Oman and, for longer-haul cargo, through Turkey, China and Singapore.

According to Reuters, the main concern is not only delay but temperature control. Many high-value medicines, including cancer treatments based on monoclonal antibodies, require tightly managed cold-chain transport and can become unusable if handling windows are missed. Executives cited by Reuters said the risk grows with every added transfer, storage stop and customs handoff along replacement routes.

Reuters also reported that some companies have begun prioritizing the most time-sensitive products while reviewing inventory buffers already inside Gulf markets. That has helped avoid immediate shortages, but it has also narrowed the margin for further disruption if airport closures or regional attacks continue.

Cancer treatment schedules face the highest exposure if delays deepen

Reuters reported that oncology medicines are among the most exposed products because many regimens depend on precise treatment intervals and specialist handling. Industry executives told Reuters that even short transport delays can create knock-on effects for hospitals and distributors if replacement inventory is not already positioned inside the region.

According to Reuters, companies have not yet reported a broad breakdown in medicine availability across Gulf markets. However, executives warned that the risk of shortages would rise if the conflict continues to disrupt aviation corridors or if additional strikes affect major logistics hubs used for pharmaceutical transit.

The disruption also underscores how the Iran war is expanding beyond direct military targets into commercial systems that support civilian healthcare. Air cargo rerouting, added customs handoffs and tighter handling windows are increasing operational stress across a supply chain built around speed, temperature control and predictable hub access.

Drugmakers activate contingency plans as Gulf logistics pressure builds

Reuters reported that pharmaceutical companies have started using contingency measures including rerouted flights, revised inventory planning and closer coordination with regional distributors to keep medicines moving into Gulf markets. Executives told Reuters that the immediate goal is to protect cold-chain integrity while preserving delivery windows for critical therapies.

Those measures may reduce short-term disruption, but they also raise transport costs and reduce flexibility if the conflict widens further. According to Reuters, the current concern is less a single point failure than the cumulative effect of longer routes, reduced cargo capacity and repeated operational interruptions across the region’s air logistics network.

The disruption adds a civilian supply-chain dimension to a conflict already affecting Gulf energy and transport infrastructure. If the war persists, healthcare import channels could come under the same sustained pressure already seen in aviation, fuel shipping and industrial logistics across the wider Gulf corridor.